Binah Capital Group (BCG)
Platform for independent financial professionals across brokerage, advisory, insurance, and practice support.
Binah Capital Group Reports Results for Second Quarter of 2026
- Assets Under Management (“AuM”) Increased 13.4% Year-over-Year to $31.6 Billion - - Increased Net Income to $0.3 Million from a net loss of $(0.7) million in the Prior Year Period - - Increased EBITDA [*] to $1.0 Million from $0.1 Million in the Prior Year Period - - Increased Total Revenue to $46.5 million from $41.5 million in prior year period - NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. (“Binah”, “Binah Capital” or the “Company”) (NASDAQ: BCG; BCGWW), a leading financial services enterprise that owns and operates a network of industry-leading firms empowering independent financial advisors, today announced results for the second quarter and six months ended June 30, 2026. "Our second quarter results demonstrate that Binah is accelerating its growth in wealth management by leveraging our differentiated platform,” stated Craig Gould, Chief Executive Officer of Binah Capital Group.
Binah Capital Group to Participate in Sidoti Micro-Cap Virtual Conference August 19-20
NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. (“Binah”, “Binah Capital” or the “Company”) (NASDAQ: BCG; BCGWW), a leading financial services enterprise that owns and operates a network of industry-leading firms empowering independent financial advisors, today announced that it will participate in the Sidoti Micro-Cap Virtual conference (link to event) on August 19-20, 2026. Presenting for the company on Thursday, August 20, 2026 at 2:30 PM ET will be Craig Gould, Chief Executive Officer, and David Shane, Chief Financial Officer.
BCG CEO: AI adoption now as high on CEOs' agenda as profits
Christoph Schweizer, CEO of Boston Consulting Group (BCG), tells CNBC's Squawk Box Europe that AI adoption is now as much on the minds of global CEOs as sales and profits, as businesses begin to understand the operational, cultural and skills-related challenges of integrating the technology into the workplace. Schweizer also discusses how he expects AI to reshape the global workforce, saying around 50% of jobs will fundamentally change, while only 10% to 15% are likely to be replaced entirely.
81% of Enterprises Report AI Initiatives Delayed, Scaled Back, or Abandoned Due to Data Permission and Governance Gaps, Finds Transcend Research
SAN FRANCISCO--(BUSINESS WIRE)--Transcend, the autonomous "can I use this data?" platform that powers every data decision to scale customer growth, released The 2026 State of Customer Data in the World of AI, a report drawn from a survey of 228 senior IT and business leaders at enterprises with 5,000 or more employees.The findings reveal a widening gap between enterprise AI ambition and the data infrastructure required to support it. Despite Boston Consulting Group (BCG) projections that $2 tril.
TVS Motor Company Ranked #1 Globally For Shareholder Value Creation In 'Durable Consumer Goods' By WirtschaftsWoche And Boston Consulting Group
TVS Motor Company, part of TVS VENU, has been ranked #1 globally in the âDurable Consumer Goods' category in the annual âBest Stocks in the World', ranking
Binah Capital Group Reports Results for First Quarter of 2026
- Assets Under Management (“AuM”) Increased 12.9% Year-over-Year to $29.0 Billion - - Increased Net Income to $1.9 Million from $1.0 million in the Prior Year - - Increased EBITDA [*] to $3.3 Million from $2.2 Million in the Prior Year - - Total Revenue of $48.7 million similar to $48.9 million in prior year period - NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. (“Binah”, “Binah Capital” or the “Company”) (NASDAQ: BCG; BCGWW), a leading financial services enterprise that owns and operates a network of industry-leading firms empowering independent financial advisors, today announced results for the quarter ended March 31, 2026. "I am pleased with our strong operational results in the first quarter, despite a sometimes challenging market, as this reflects the continuing growth of our differentiated platform,” stated Craig Gould, Chief Executive Officer of Binah Capital Group.
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-month landmark and 55% complete response rate at the 12-month landmark in BCG-Naïve patients
Groundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation
More than 90% of patients surveyed who underwent bladder removal or received BCG report negative impact on most aspects of their lives Among patients treated with BCG, three- quarters describe managing the treatment- related physical symptoms as humiliating Patients and urologists point to the importance of advancing treatments that may better reflect patient preferences and quality-of-life considerations WASHINGTON, May 14, 2026 /PRNewswire/ -- A new global survey of patient and urologist perception and experience—conducted in collaboration with leading bladder cancer professional and patient organizations—reveals the physical, mental, and emotional toll associated with standard-of-care therapies for bladder cancer, including surgery to remove the bladder and Bacillus Calmette-Guérin (BCG) treatment. Released ahead of the American Urological Association (AUA) Annual Meeting, the findings highlight patient experiences that may not always be fully surfaced and discussed during care, pointing to opportunities to strengthen support and continue advancing innovative treatment approaches.
Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and a 94% CR rate at any time and a durable 80% CR rate at 12 months in the BCG-unresponsive subpopulation, reinforcing best-in-class potential in NMIBC On track to initiate Phase 3 RESCUE registrational program in second line (2L) BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026 Filed provisional patent application with the USPTO in April 2026 covering NDV-01 pharmaceutical formulations and methods of treatment; if issued, patents claiming priority to the provisional filing would have a term until April 2047 Relmada will feature two NDV-01 presentations at the American Urological Association Annual Meeting (AUA2026), highlighting the 12-month Phase 2 data and the Phase 3 RESCUE program design and rationale Cash balance of $234.0 million as of March 31, 2026 expected to fund operations through 2029, including completion of the NDV-01 Phase 3 RESCUE program Management to host a conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla., May 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today reported financial results for the first quarter ended March 31, 2026 and provided a corporate update.
CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
-First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented-
Binah Capital Group (NASDAQ:BCG) Shares Down 9% – Here’s What Happened
Binah Capital Group, Inc. (NASDAQ: BCG - Get Free Report)'s stock price fell 9% during mid-day trading on Thursday. The company traded as low as $1.82 and last traded at $1.91. 144,432 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 1,703,621 shares. The stock had previously closed
Binah Capital Group Reports Results for Fourth Quarter and Full Year 2025
– Grew Total Revenue 11% Year-over-Year to $187.1 Million – – Assets Under Management (“AuM”) Increased 11% Year-over-Year to $29.9 Billion – – Net Income of $2.3 Million – – Increased EBITDA [ * ] to $5.4 Million from $2.0 Million in the Prior Year – NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. (“Binah”, “Binah Capital” or the “Company”) (NASDAQ: BCG; BCGWW), a leading financial services enterprise that owns and operates a network of industry-leading firms empowering independent financial advisors, today announced results for the quarter and full year ended December 31, 2025. “We completed our first full year as a public company with strong results in the fourth quarter, which reflects the continuing growth of our differentiated platform,” stated Craig Gould, Chief Executive Officer of Binah Capital Group.
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBC BCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any time Tolerability profile remains favorable – no ≥ Grade 3 treatment-related adverse events and no treatment-related discontinuations Data reinforces advancement of NDV-01 into Phase 3 RESCUE registrational program in second line (2L) BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026 CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced 12-month interim data from its ongoing Phase 2 trial evaluating NDV-01 in patients with high-risk non-muscle invasive bladder cancer (NMIBC).
Binah Capital Group (NASDAQ:BCG) versus Barings Participation Investors (NYSE:MPV) Financial Comparison
Barings Participation Investors (NYSE: MPV - Get Free Report) and Binah Capital Group (NASDAQ: BCG - Get Free Report) are both small-cap finance companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation. Analyst Ratings This is a
Binah Capital Group (NASDAQ:BCG) vs. KKR & Co. Inc. (NYSE:KKR) Critical Comparison
KKR and Co. Inc. (NYSE: KKR - Get Free Report) and Binah Capital Group (NASDAQ: BCG - Get Free Report) are both finance companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations. Risk and Volatility KKR and
CG Oncology Undervalued Going Into A Busy 2026
CG Oncology is positioned as a leading contender in high-risk BCG-unresponsive NMIBC, with its oncolytic adenovirus, cretostimogene grenadenorepvec (creto). Creto's efficacy and safety data rival JNJ's Inlexo, with a 75.5% any-time CR rate, similar 12mo/24mo CR rates, a longer response duration, and notably fewer Grade 3+ adverse events. CGON targets $2B peak revenue in its primary indication, with meaningful upside from intermediate-risk, BCG-naïve, and muscle-invasive bladder cancer opportunities.
Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
New data from Cohort 4 of the SunRISe-1 study show more than 95 percent of patients remained progression free at one year, with more than 92 percent not undergoing bladder removal Patients with this type of bladder cancer have limited choices beyond radical cystectomy, highlighting the need for newer therapies for bladder preservation RARITAN, N.J. , Dec. 5, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today that new data from the investigational Cohort 4 of the Phase 2b SunRISe-1 study show treatment with gemcitabine intravesical system resulted in high one-year disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS) rates in patients with Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk, papillary-only non-muscle invasive bladder cancer (NMIBC).1 These data were featured as a late-breaking oral presentation at the Society of Urologic Oncology (SUO) 2025 Annual Meeting and build upon data presented at the 2025 American Urological Association (AUA) Annual Meeting.
Critical Contrast: Binah Capital Group (NASDAQ:BCG) & Fairfax India (OTCMKTS:FFXDF)
Fairfax India (OTCMKTS:FFXDF - Get Free Report) and Binah Capital Group (NASDAQ: BCG - Get Free Report) are both finance companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, dividends, earnings, valuation, profitability, risk and institutional ownership. Profitability This table compares Fairfax India and
Binah Capital Group to Participate in NobleCon21 Conference in December
NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. (“Binah”, “Binah Capital” or the “Company”) (NASDAQ: BCG; BCGWW), a leading financial services enterprise that owns and operates a network of industry-leading firms empowering independent financial advisors, today announced that it will participate in the NobleCon21 conference, Noble Capital Markets' 21st Annual Emerging Growth Equity Conference, in Boca Raton, FL on December 4, 2025. Presenting for the company at 9:30 AM ET in Presentation Room 5 will be Craig Gould, Chief Executive Officer, and David Shane, Chief Financial Officer.